| ［1］ |
Turpin D, Truchetet ME, Faustin B, et al. Role of extracellular vesicles in autoimmune diseases［J］. Autoimmun Rev, 2016, 15（2）: 174⁃183. DOI: 10.1016/j.autrev.2015.11.004.
|
| ［2］ |
Jung C, Drummer K, Oelzner P, et al. The association between endothelial microparticles and inflammation in patients with systemic sclerosis and Raynaud′s phenomenon as detected by functional imaging［J］. Clin Hemorheol Microcirc, 2015, 61（3）: 549⁃557. DOI: 10.3233/CH⁃151956.
|
| ［3］ |
Distler JH, Akhmetshina A, Dees C, et al. Induction of apoptosis in circulating angiogenic cells by microparticles［J］. Arthritis Rheum, 2011, 63（7）: 2067⁃2077. DOI: 10.1002/art.30361.
|
| ［4］ |
Guiducci S, Distler JH, Jüngel A, et al. The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis［J］. Arthritis Rheum, 2008, 58（9）: 2845⁃2853. DOI: 10.1002/art.23735.
|
| ［5］ |
Nomura S, Niki M, Nisizawa T, et al. Microparticles as biomarkers of blood coagulation in cancer［J］. Biomark Cancer, 2015, 7: 51⁃56. DOI: 10.4137/BIC.S30347.
|
| ［6］ |
Tran TH, Mattheolabakis G, Aldawsari H, et al. Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases［J］. Clin Immunol, 2015, 160（1）: 46⁃58. DOI: 10.1016/j.clim.2015.03.021.
|
| ［7］ |
Dunne JV, Bankole J, Keen KJ. Systematic review of the role of microparticles in systemic sclerosis［J］. Curr Rheumatol Rev, 2013, 9（4）: 279⁃300. DOI: 10.2174/1573397109666140103001139.
|
| ［8］ |
Iversen LV, Østergaard O, Ullman S, et al. Circulating micropar⁃ticles and plasma levels of soluble E⁃ and P⁃selectins in patients with systemic sclerosis［J］. Scand J Rheumatol, 2013, 42（6）: 473⁃482. DOI: 10.3109/03009742.2013.796403.
|
| ［9］ |
Iversen LV, Ullman S, Østergaard O, et al. Cross⁃sectional study of soluble selectins, fractions of circulating microparticles and their relationship to lung and skin involvement in systemic sclerosis［J］. BMC Musculoskelet Disord, 2015, 16: 191. DOI: 10. 1186/s12891⁃015⁃0653⁃8.
|
| ［10］ |
Oyabu C, Morinobu A, Sugiyama D, et al. Plasma platelet⁃derived microparticles in patients with connective tissue diseases［J］. J Rheumatol, 2011, 38（4）: 680⁃684. DOI: 10.3899/jrheum.100780.
|
| ［11］ |
Bourji K, Meyer A, Chatelus E, et al. High reactive oxygen species in fibrotic and nonfibrotic skin of patients with diffuse cutaneous systemic sclerosis［J］. Free RadicBiol Med, 2015, 87: 282⁃289. DOI: 10.1016/j.freeradbiomed.2015.07.002.
|
| ［12］ |
Maugeri N, Rovere⁃Querini P, Baldini M, et al. Oxidative stress elicits platelet/leukocyte inflammatory interactions via HMGB1: a candidate for microvessel injury in sytemicsclerosis［J］. Antioxid Redox Signal, 2014, 20（7）: 1060⁃1074. DOI: 10.1089/ars.2013. 5298.
|
| ［13］ |
Yoshizaki A, Komura K, Iwata Y, et al. Clinical significance of serum HMGB⁃1 and sRAGE levels in systemic sclerosis: association with disease severity［J］. J ClinImmunol, 2009, 29（2）: 180⁃189. DOI: 10.1007/s10875⁃008⁃9252⁃x.
|
| ［14］ |
Maugeri N, Franchini S, Campana L, et al. Circulating platelets as a source of the damage⁃associated molecular pattern HMGB1 in patients with systemic sclerosis［J］. Autoimmunity, 2012, 45（8）: 584⁃587. DOI: 10.3109/08916934.2012.719946.
|
| ［15］ |
Ayer LM, Sénecal JL, Martin L, et al. Antibodies to high mobility group proteins in systemic sclerosis［J］. J Rheumatol, 1994, 21（11）: 2071⁃2075.
|
| ［16］ |
Kavian N, Marut W, Servettaz A, et al. Pantethine prevents murine systemic sclerosis through the inhibition of microparticle shedding［J］. Arthritis Rheumatol, 2015, 67（7）: 1881⁃1890. DOI: 10.1002/art.39121.
|
| ［17］ |
Schilders G, Raijmakers R, Malmegrim KC, et al. Caspase⁃mediated cleavage of the exosome subunit PM/Scl⁃75 during apoptosis［J］. Arthritis Res Ther, 2007, 9（1）: R12. DOI: 10.1186/ar2119.
|
| ［18］ |
Mahler M, Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights［J］. Autoimmun Rev, 2007, 6（7）: 432⁃437. DOI: 10.1016/j.autrev. 2007.01.013.
|
| ［19］ |
Mahler M, Fritzler MJ. PM1⁃Alpha ELISA: the assay of choice for the detection of anti⁃PM/Scl autoantibodies?［J］. Autoimmun Rev, 2009, 8（5）: 373⁃378. DOI: 10.1016/j.autrev.2008.12.001.
|
| ［20］ |
Wodkowski M, Hudson M, Proudman S, et al. Clinical correlates of monospecific anti⁃PM75 and anti⁃PM100 antibodies in a tri⁃nation cohort of 1574 systemic sclerosis subjects［J］. Autoimmunity, 2015, 48（8）: 542⁃551. DOI: 10.3109/08916934. 2015.1077231.
|
| ［21］ |
Schilders G, Egberts WV, Raijmakers R, et al. C1D is a major autoantibody target in patients with the polymyositis⁃scleroderma overlap syndrome［J］. Arthritis Rheum, 2007, 56（7）: 2449⁃2454. DOI: 10.1002/art.22710.
|
| ［22］ |
Robbins PD, Dorronsoro A, Booker CN. Regulation of chronic inflammatory and immune processes by extracellular vesicles［J］. J Clin Invest, 2016, 126（4）: 1173⁃1180. DOI: 10.1172/JCI81131.
|
| ［23］ |
De Toro J, Herschlik L, Waldner C, et al. Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications［J］. Front Immunol, 2015, 6: 203. DOI: 10.3389/fimmu.2015.00203.
|
